The elevated P/S ratio is likely an artifact of the company's revenue collapse rather than a signal of premium growth expectations. Given the lack of forward earnings and the absence of a clear path to commercialization, this valuation multiple provides little utility for fundamental assessment and may mask the underlying risk of total equity dilution.

The high gross margin reflects the absence of significant cost of goods sold, which is typical for a pre-revenue biotech firm, but it fails to account for the massive R&D and administrative overhead required to sustain operations. Investors should monitor whether the company can transition to a royalty-based model, as the current operating losses suggest the existing cost structure is unsustainable.

The extreme volatility in days sales outstanding and days payable outstanding suggests significant friction in the company's cash conversion cycle. This inefficiency indicates that management is struggling to manage vendor relationships and revenue collection, which further complicates the company's already precarious liquidity position.

While the current ratio suggests an ability to cover short-term obligations, the lack of recurring revenue means that the company is entirely dependent on external financing to maintain its operations. The rapid erosion of cash over the last ten quarters warrants close monitoring, as the current runway appears insufficient to support long-term clinical milestones.